Why the study?
Do volatile general anesthetics prevent ischemia and reperfusion injury in patients undergoing cardiac and noncardiac surgery?
Do volatile general anesthetics prevent ischemia and reperfusion injury in patients undergoing cardiac and noncardiac surgery?
While volatile anesthetics demonstrate experimental cardioprotective effects against ischemia-reperfusion injury, their definitive impact on hard clinical outcomes in surgical patients remains to be established.
Does not support preferential volatile use for cardioprotection; leaves open effects on postoperative mortality in cardiac and noncardiac surgery.
Cardiac surgery and some noncardiac procedures are associated with a significant risk of perioperative cardiac morbid events. Experimental data indicate that clinical concentrations of volatile general anesthetics protect the myocardium from ischemia and reperfusion injury, as shown by decreased infarct size and a more rapid recovery of contractile function on reperfusion. These anesthetics may also mediate protective effects in other organs, such as the brain and kidney. Recently, a number of reports have indicated that these experimentally observed protective effects may also have clinical implications in cardiac surgery. However, the impact of the use of volatile anesthetics on outcome measures, such as postoperative mortality and recovery in cardiac and noncardiac surgery, is yet to be determined.
No takes yet. Share an insight, caveat, or question.
Hert et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: